{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:43:06Z","timestamp":1772811786641,"version":"3.50.1"},"reference-count":52,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Science Foundation","award":["21-75-10105"],"award-info":[{"award-number":["21-75-10105"]}]},{"name":"Russian Science Foundation","award":["0245-2021-0009"],"award-info":[{"award-number":["0245-2021-0009"]}]},{"name":"Russian Science Foundation","award":["121031300041-4"],"award-info":[{"award-number":["121031300041-4"]}]},{"name":"Russian State-funded budget project of ICBFM SB RAS","award":["21-75-10105"],"award-info":[{"award-number":["21-75-10105"]}]},{"name":"Russian State-funded budget project of ICBFM SB RAS","award":["0245-2021-0009"],"award-info":[{"award-number":["0245-2021-0009"]}]},{"name":"Russian State-funded budget project of ICBFM SB RAS","award":["121031300041-4"],"award-info":[{"award-number":["121031300041-4"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The S-protein is the major antigen of the SARS-CoV-2 virus, against which protective antibodies are generated. The S-protein gene was used in adenoviral vectors and mRNA vaccines against COVID-19. While the primary function of antibodies is to bind to antigens, catalytic antibodies can hydrolyze various substrates, including nucleic acids, proteins, oligopeptides, polysaccharides, and some other molecules. In this study, antibody fractions with affinity for RBD and S-protein (RBD-IgG and S-IgG) were isolated from the blood of COVID-19 patients vaccinated with Sputnik V. The fractions were analyzed for their potential to hydrolyze 18-mer oligopeptides corresponding to linear fragments of the SARS-CoV-2 S-protein. Here, we show that the IgG antibodies hydrolyze six out of nine oligopeptides efficiently, with the antibodies of COVID-19-exposed donors demonstrating the most significant activity. The IgGs of control donors not exposed to SARS-CoV-2 were found to be inactive in oligopeptide hydrolysis. The antibodies of convalescents and vaccinated patients were found to hydrolyze oligopeptides in a wide pH range, with the optimal pH range between 6.5 and 7.5. The hydrolysis of most oligopeptides by RBD-IgG antibodies is inhibited by thiol protease inhibitors, whereas S-IgG active centers generally combine several types of proteolytic activities. Ca2+ ions increase the catalytic activity of IgG preparations containing metalloprotease-like active centers. Thus, the proteolytic activity of natural antibodies against the SARS-CoV-2 protein is believed to be due to the similarity of catalytic antibodies\u2019 active centers to canonical proteases. This work raises the question of the possible physiological role of proteolytic natural RBD-IgG and S-IgG resulting from vaccination and exposure to COVID-19.<\/jats:p>","DOI":"10.3390\/vaccines11091494","type":"journal-article","created":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T06:36:45Z","timestamp":1694932605000},"page":"1494","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Natural Antibodies Produced in Vaccinated Patients and COVID-19 Convalescents Recognize and Hydrolyze Oligopeptides Corresponding to the S-Protein of SARS-CoV-2"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1270-7164","authenticated-orcid":false,"given":"Anna M.","family":"Timofeeva","sequence":"first","affiliation":[{"name":"SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk 630090, Russia"},{"name":"Faculty of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-8171","authenticated-orcid":false,"given":"Sergey E.","family":"Sedykh","sequence":"additional","affiliation":[{"name":"SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk 630090, Russia"},{"name":"Faculty of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana A.","family":"Sedykh","sequence":"additional","affiliation":[{"name":"SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk 630090, Russia"},{"name":"Faculty of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4988-8923","authenticated-orcid":false,"given":"Georgy A.","family":"Nevinsky","sequence":"additional","affiliation":[{"name":"SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk 630090, Russia"},{"name":"Faculty of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s43441-023-00536-y","article-title":"Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future\u2014An Industry View","volume":"57","author":"Geraci","year":"2023","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e011879","DOI":"10.1136\/bmjgh-2023-011879","article-title":"Factors, enablers and challenges for COVID-19 vaccine development","volume":"8","author":"Excler","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2191577","DOI":"10.1080\/21645515.2023.2191577","article-title":"Tracking the COVID-19 vaccines: The global landscape","volume":"19","author":"Yadav","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_4","first-page":"CD015477","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Ghosn","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1473-3099(22)00140-2","article-title":"Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: A test-negative, case-control study","volume":"22","author":"Andrews","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1367-5931(00)00208-8","article-title":"Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics","volume":"5","author":"Irving","year":"2001","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"FSO832","DOI":"10.2144\/fsoa-2022-0048","article-title":"State of the art in epitope mapping and opportunities in COVID-19","volume":"9","author":"Hamed","year":"2023","journal-title":"Future Sci. OA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molimm.2012.06.001","article-title":"Structural analysis of B-cell epitopes in antibody:protein complexes","volume":"53","author":"Kringelum","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lim, H.X., Masomian, M., Khalid, K., Kumar, A.U., MacAry, P.A., and Poh, C.L. (2022). Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084341"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1039\/D1CB00169H","article-title":"An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies","volume":"2","author":"Whitehead","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/20477724.2022.2072456","article-title":"Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design","volume":"117","author":"Lim","year":"2023","journal-title":"Pathog. Glob. Health"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Farrera-Soler, L., Daguer, J.-P., Barluenga, S., Vadas, O., Cohen, P., Pagano, S., Yerly, S., Kaiser, L., Vuilleumier, N., and Winssinger, N. (2020). Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. PLoS ONE, 15.","DOI":"10.1101\/2020.06.15.20131391"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1007\/s12010-022-04183-1","article-title":"Catalytic Antibodies: Design, Expression, and Their Applications in Medicine","volume":"195","author":"Zhao","year":"2023","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/bmc-2021-0021","article-title":"Antibodies targeting enzyme inhibition as potential tools for research and drug development","volume":"12","year":"2021","journal-title":"Biomol. Concepts"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/oxfordjournals.jbchem.a124385","article-title":"Recent Advances in Abzyme Studies1","volume":"115","author":"Suzuki","year":"1994","journal-title":"J. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ermakov, E.A., Nevinsky, G.A., and Buneva, V.N. (2020). Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155392"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/IAI.00202-17","article-title":"Antibody-Mediated Catalysis in Infection and Immunity","volume":"85","author":"Bowen","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/rheumatology\/keh054","article-title":"The pathogenetic role of immunoglobulin G from patients with systemic lupus erythematosus in the development of lupus pleuritis","volume":"43","author":"Guo","year":"2003","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF02900358","article-title":"Natural catalytic antibodies","volume":"5","author":"Paul","year":"1996","journal-title":"Mol. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1073\/pnas.0509849103","article-title":"Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen","volume":"103","author":"Ponomarenko","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12264-008-2429-8","article-title":"Immunologic pathogenesis of multiple sclerosis","volume":"24","author":"Guo","year":"2008","journal-title":"Neurosci. Bull."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/jamaneurol.2018.1055","article-title":"Anti\u2013Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Central Nervous System Demyelination\u2014A Novel Disease Entity?","volume":"75","author":"Weber","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4049\/jimmunol.180.2.1258","article-title":"Recognition and Degradation of Myelin Basic Protein Peptides by Serum Autoantibodies: Novel Biomarker for Multiple Sclerosis","volume":"180","author":"Belogurov","year":"2008","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Timofeeva, A.M., Dmitrenok, P.S., Konenkova, L.P., Buneva, V.N., and Nevinsky, G.A. (2013). Multiple Sites of the Cleavage of 21- and 25-Mer Encephalytogenic Oligopeptides Corresponding to Human Myelin Basic Protein (MBP) by Specific Anti-MBP Antibodies from Patients with Systemic Lupus Erythematosus. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0051600"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Timofeeva, A., Sedykh, S., and Nevinsky, G. (2022). Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. Vaccines, 10.","DOI":"10.3390\/vaccines10030384"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gushchin, V.A., Dolzhikova, I.V., Shchetinin, A.M., Odintsova, A.S., Siniavin, A.E., Nikiforova, M.A., Pochtovyi, A.A., Shidlovskaya, E.V., Kuznetsova, N.A., and Burgasova, O.A. (2021). Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines, 9.","DOI":"10.3390\/vaccines9070779"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Devi, M.J., Gaffar, S., and Hartati, Y.W. (2022). A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer response. Anal. Biochem., 658.","DOI":"10.1016\/j.ab.2022.114902"},{"key":"ref_28","first-page":"CD013652","article-title":"Antibody tests for identification of current and past infection with SARS-CoV-2","volume":"11","author":"Fox","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43088-023-00342-3","article-title":"Screening and confirmation tests for SARS-CoV-2: Benefits and drawbacks","volume":"12","author":"Shafie","year":"2023","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"923525","DOI":"10.3389\/fpubh.2022.923525","article-title":"Accuracy of serological tests for COVID-19: A systematic review and meta-analysis","volume":"10","author":"Zheng","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Timofeeva, A.M., Sedykh, S.E., Ermakov, E.A., Matveev, A.L., Odegova, E.I., Sedykh, T.A., Shcherbakov, D.N., Merkuleva, I.A., Volosnikova, E.A., and Nesmeyanova, V.S. (2022). Natural IgG against S-Protein and RBD of SARS-CoV-2 Do Not Bind and Hydrolyze DNA and Are Not Autoimmune. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213681"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"W431","DOI":"10.1093\/nar\/gkab314","article-title":"Mol* Viewer: Modern web app for 3D visualization and analysis of large biomolecular structures","volume":"49","author":"Sehnal","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1100\/tsw.2010.98","article-title":"Natural Catalytic Antibodies in Norm, Autoimmune, Viral, and Bacterial Diseases","volume":"10","author":"Nevinsky","year":"2010","journal-title":"Sci. World J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/MMBR.62.3.597-635.1998","article-title":"Molecular and Biotechnological Aspects of Microbial Proteases","volume":"62","author":"Rao","year":"1998","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1582-4934.2009.00738.x","article-title":"Affinity and catalytic heterogeneity of polyclonal myelin basic protein-hydrolyzing IgGs from sera of patients with multiple sclerosis","volume":"14","author":"Legostaeva","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1070\/RC2005v074n01ABEH001159","article-title":"V Catalytic sites of hydrolases: Structures and catalytic cycles","volume":"74","author":"Varfolomeev","year":"2005","journal-title":"Russ. Chem. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.1085515","article-title":"A Perspective on Enzyme Catalysis","volume":"301","author":"Benkovic","year":"2003","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ijch.201300144","article-title":"From Catalytic Mechanism to Rational Design of Reversible Covalent Inhibitors of Serine and Cysteine Hydrolases","volume":"54","author":"Shokhen","year":"2014","journal-title":"Isr. J. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/jmr.1143","article-title":"Affinity and catalytic heterogeneity and metal-dependence of polyclonal myelin basic protein-hydrolyzing IgGs from sera of patients with systemic lupus erythematosus","volume":"24","author":"Bezuglova","year":"2011","journal-title":"J. Mol. Recognit."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s44149-023-00075-x","article-title":"Roles of host proteases in the entry of SARS-CoV-2","volume":"3","author":"Zabiegala","year":"2023","journal-title":"Anim. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virs.2023.04.009","article-title":"A novel bat coronavirus with a polybasic furin-like cleavage site","volume":"38","author":"Zhu","year":"2023","journal-title":"Virol. Sin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"147144","DOI":"10.1016\/j.gene.2022.147144","article-title":"Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection","volume":"856","author":"Wang","year":"2023","journal-title":"Gene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/jmv.27845","article-title":"In silico analysis of mutations near S1\/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain","volume":"94","author":"Beaudoin","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2220582","DOI":"10.1080\/22221751.2023.2220582","article-title":"SARS-CoV-2 spike S2-specific neutralizing antibodies","volume":"12","author":"Li","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.chembiol.2023.05.011","article-title":"Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization","volume":"30","author":"McConnell","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kuznetsov, A., Voronina, A., Govorun, V., and Arapidi, G. (2020). Critical Review of Existing MHC I Immunopeptidome Isolation Methods. Molecules, 25.","DOI":"10.3390\/molecules25225409"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Choe, W., Durgannavar, T., and Chung, S. (2016). Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides. Materials, 9.","DOI":"10.3390\/ma9120994"},{"key":"ref_51","first-page":"166","article-title":"Affinity Chromatography of Native and Recombinant Proteins from Receptors for Insulin and IGF-I to Recombinant Single Chain Antibodies","volume":"6","year":"2015","journal-title":"Front. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ermakov, E.A., Parshukova, D.A., Nevinsky, G.A., and Buneva, V.N. (2020). Natural Catalytic IgGs Hydrolyzing Histones in Schizophrenia: Are They the Link between Humoral Immunity and Inflammation?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197238"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1494\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:51:57Z","timestamp":1760129517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["vaccines11091494"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11091494","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]}}}